FDA Turns Down F2G’s Antifungal, But Firm Plots Comeback As Trial Completes Accrual

 
• By Alaric DeArment
  
F2G plans to give its NDS for antifungal drug olorofim another shot • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip